Perino J, Ramaroson H, Ong N, Bezin J, Gilleron V, Daveluy A, Tournier M. General hospital admissions in young and middle-aged people who use psychoactive substances: Impact of Covid-19 lockdowns. Int J Drug Policy. 2023 Jun 8;118:104082. doi: 10.1016/j.drugpo.2023.104082. Epub ahead of print. PMID: 37336071; PMCID: PMC10247883.
Roy S, Eiden C, Nogue E, Picot MC, Donnadieu-Rigole H, Peyrière H. Follow-up of patients hospitalized for cocaine detoxification. Inpatient cocaine detoxification. Therapie. 2022 Dec 2:S0040-5957(22)00271-2. doi: 10.1016/j.therap.2022.11.008. Epub ahead of print. PMID: 36517301.
Mezaache S, Turlure F, Fredon N, Le Brun Gadelius M, Micallef J, Frauger E. Prévention des surdoses opioïdes et diffusion de naloxone (programme POP) : résultats d’un état des lieux réalisé auprès des structures d’addictologie [Opioid overdose prevention and naloxone diffusion (POP program): Results of an overview conducted among addiction specialized centres]. Therapie. 2023 Mar 15:S0040-5957(23)00057-4. French.
Aquizerate, A., Laforgue, EJ., Istvan, M. et al. Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study. Int J Ment Health Addiction (2023).
Soeiro T, Pradel V, Lapeyre-Mestre M, Micallef J. Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: A nationwide, repeated cross-sectional study. Addiction. 2023 May 19. doi: 10.1111/add.16261. Epub ahead of print. PMID: 37203878
L. Diaz, C. Eiden, E. Jouanjus et al., Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020, Therapies
Aquizerate A, Laforgue EJ, Istvan M, Rousselet M, Gerardin M, Jouanjus E, Libert F; French Addictovigilance Network; Guerlais M, Victorri-Vigneau C. French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change. Eur J Public Health. 2023 Feb 7:ckad003. doi: 10.1093/eurpub/ckad003. Epub ahead of print.
Pour compléter les éléments d’actualité concernant les problématiques d’usage du protoxyde d’azote, vous trouverez les données récentes, à l’échelle européenne, publiées par l’Observatoire Européen des Drogues et des Toxicomanies (l’EMCDDA), en décembre 2022. Recreational use of nitrous oxide — a growing concern for Europe. Leon Van Aerts, Joanna de Morais (1), Michael Evans-Brown (1), Rita
Rapport de l’EMCDDA sur le protoxyde d’azote Lire la suite »
Peyriere H, Jacquet JM, Peries M, Tribout V, Broche B, Mauboussin JM, Makinson A, Perrollaz C, Ferreyra M, Rouanet I, Montoya-Ferrer A, El-Majjaoui S, Corriol-Bonifas F, Fraisse T, Grau F, Laureillard D, Nagot N, Reynes J, Donnadieu-Rigole H. Chemsex in HIV pre-exposure prophylaxis users: Assessment of mood disorders and addictive behavior. Fundam Clin Pharmacol. 2022 Nov 20.
Robert M, Jouanjus E, Khouri C, Fouilhé Sam-Laï N, Revol B. The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2022 Nov 4. doi: 10.1111/add.16081. Epub ahead of print. PMID: 36331523.